Rituximab for endometriosis: Unlikely translatability from oncology due to safety concerns?
Journal of Reproductive Immunology · 2023
DOI: 10.1016/j.jri.2023.103967 ↗Kurz gefasst
Leserbrief in der Zeitschrift Journal of Reproductive Immunology, 2023. Verfasst von Fabio Barra und 5 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Obstetrics and Gynecology, P.O. "Ospedale del Tigullio"- ASL4, Metropolitan Area of Genoa, Genoa, Italy; Department of Health Sciences (DISSA…. Hauptthemen laut MEDLINE: Endometriosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 5 Literaturangaben.
Abstract (Originalsprache)
This letter discusses the article "The Effects of Rituximab on Experimental Endometriosis Model in Rats" by Dogan et al., which evaluated the potential therapeutic efficacy of rituximab in an experimental animal model of endometriosis. While the study showed promising results in decreasing the volume of endometriotic implants and differences in B-cell count and fibrosis score, rituximab is typically used as a therapy for B lymphocyte malignancies and has potential short-term and long-term side effects. Additionally, animal models for endometriosis have limitations, and novel models are still being developed. Therefore, further preclinical research is necessary to evaluate the safety and efficacy of rituximab as a potential treatment for endometriosis in humans.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Unit of Obstetrics and Gynecology, P.O. "Ospedale del Tigullio"- ASL4, Metropolitan Area of Genoa, Genoa, Italy; Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy. Electronic address: fabio.barra…
- Unit of Obstetrics and Gynecology, P.O. "Ospedale del Tigullio"- ASL4, Metropolitan Area of Genoa, Genoa, Italy; Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI),…
- Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI), University of Genoa, Genoa, Italy; Academic Unit of Obstetrics and Gynecology, IRCCS Ospedale Policlinico San Ma…
- Unit of Obstetrics and Gynecology, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
- Unit of Obstetrics and Gynecology, P.O. "Ospedale del Tigullio"- ASL4, Metropolitan Area of Genoa, Genoa, Italy.
- Unit of Mutagenesis and Cancer Prevention, IRCCS Ospedale Policlinico San Martino, Genoa, Italy; Department of Experimental Medicine (DIMES), University of Genoa, Genoa, Italy.
Zitieren
APA
Barra, F., Perrone, U., Ferrero, S., Gustavino, C., Bogliolo, S., & Izzotti, A. (2023). Rituximab for endometriosis: Unlikely translatability from oncology due to safety concerns?. Journal of Reproductive Immunology. https://doi.org/10.1016/j.jri.2023.103967
Vancouver
Barra F, Perrone U, Ferrero S, Gustavino C, Bogliolo S, Izzotti A. Rituximab for endometriosis: Unlikely translatability from oncology due to safety concerns?. Journal of Reproductive Immunology. 2023. doi:10.1016/j.jri.2023.103967
BibTeX
@article{Barra2023,
author = {Barra, Fabio and Perrone, Umberto and Ferrero, Simone and Gustavino, Claudio and Bogliolo, Stefano and Izzotti, Alberto},
title = {Rituximab for endometriosis: Unlikely translatability from oncology due to safety concerns?},
journal = {Journal of Reproductive Immunology},
year = {2023},
doi = {10.1016/j.jri.2023.103967}
}
EUVIMED